- Cergentis bv
Cergentis provides services and kits based on its proprietary 'Targeted Locus Amplification' (TLA) technology.
Cergentis’ mission is to improve the quality of genetic research and human healthcare by providing services and kits that enable the cost-effective complete sequencing of relevant genes and genomic loci.
Cergentis was established in 2012 as a spin-off from the Royal Netherlands Academy of Arts and Sciences (KNAW) and its Hubrecht Institute for Developmental Biology & Stem Cell Research.
Cergentis works with and for leading research institutes, diagnostic labs and pharmaceutical and biotech companies globally.